Sign up for free insights newsletter
IN

Indegene Ltd

INDGNNSE

Need professional-grade analysis? Visit stockanalysis.com

₹440.65
-2.68%
End of day
Market Cap

$104.30B

P/E Ratio

23.81

Employees

4,158

Dividend Yield

N/A

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino-2.56-2.53-2.28-2.43
Calmar-4.75-2.75-1.59-2.68
Sharpe-1.82-1.89-1.73-1.80
Omega0.530.620.690.63
Martin-8.43-5.61-3.23-5.18
Ulcer8.009.4712.7810.62

Indegene Ltd (INDGN) Price Performance

Indegene Ltd (INDGN) trades on NSE in INR. The company is classified in the Healthcare sector under the Health Information Services industry. The stock currently trades at INR440.65, down 2.68% from the previous close.

Over the past year, INDGN has traded between a low of INR429.25 and a high of INR589.55. The stock has lost 23.5% over this period. It is currently 25.3% below its 52-week high.

Indegene Ltd has a market capitalization of $104.30B, with a price-to-earnings ratio of 23.81.

About Indegene Ltd

Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.

Company Info

Exchange
NSE
Currency
INR
Country
India

Financial Metrics

Revenue (TTM)
$32.63B
EBITDA
$5.52B
Profit Margin
13.46%
EPS (TTM)
18.23
Book Value
119.56

Technical Indicators

52 Week High
₹596.80
52 Week Low
₹427.25
50 Day MA
₹485.78
200 Day MA
₹537.30
Beta
N/A

Valuation

Trailing P/E
23.81
Forward P/E
N/A
Price/Sales
3.20
Price/Book
3.72
Enterprise Value
$95.08B